Eric Magliulo, MD
Nephrology · Omaha, NENPI 1336701689
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,525 of the $9,011 with a category attached, or 61.3%. Novartis accounts for 89.7% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $8,734, more than ten times the $86 reported in 2023.
Across 67 payments — averaging $134.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$8K
- ANI Pharmaceuticals, Inc.$209
- Calliditas Therapeutics US Inc.$106
- Otsuka Pharmaceutical Development & Commercialization, Inc.$104
- Fresenius USA Marketing, Inc.$95
- Travere Therapeutics, Inc.$63
- plus $355 from 12 others
What the payments were for
- Consulting fees$5,52561%
- Travel & lodging$2,03323%
- Food & beverage$1,35015%
- Education$1041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fabhalta$7,880
How this compares
$9,011 in reported general payments places this provider in the 85th percentile of 60 nephrology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 16 | $11,336 |
| Potassium Citrate ErPotassium Citrate | 12 | $1,631 |
| Potassium Chloride | 12 | $521 |
| Losartan Potassium | 48 | $338 |
| Amlodipine Besylate | 35 | $251 |
| Torsemide | 18 | $238 |
| Carvedilol | 19 | $147 |
| Indapamide | 12 | $137 |
| Furosemide | 18 | $80 |
| Chlorthalidone | 12 | $69 |
| Hydrochlorothiazide | 12 | $48 |
| Lisinopril | 19 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $40 | $11,33616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 60 nephrology providers in Nebraska.
Other nephrology in Omaha
- Richard LundOmaha$378K
- Jeffrey PasserOmaha$146K
- Roslyn MannonOmaha$64K
- Troy PlumbOmaha$17K
- Prasanth RavipatiOmaha$7K
- Joseph BastOmaha$5K
- Stefan HemmingsOmaha$5K
- Sunil JagadeshOmaha$4K
- Judd BauerOmaha$3K
- Mohammed NazmulOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.